News

New FAQs due to Corona/Covid-19 virus outbreak- update 08.04.2020

Published on | 5 years ago

Programmes ERC Horizon 2020 H2020 L+F

The new FAQs handle about the following issues due to the current COVID-19/Corona outbreak:

  • FAQ 13241: impossibility to fulfill  PI time commitment obligations in ERC grants
  • FAQ 13240: public procurement when difficulties in implementing procurement contracts
  • FAQ 13239: documents to be kept to prove impact of "force majeur" or dealys in submission of deliverables, reports orimplementation of the action
  • FAQ 13238: flexibility for lump sum pilot grants when work packages cannot be completed?
  • FAQ 13237: how to work with signing/countersigning time sheets?
  • FAQ 13236: cost of equipment purchased exclusively for the action and cannot be used?
  • FAQ 13235: flexibility in releation to usual travel cost practices

They are are listed on the ERA Corona platform page of the Commission together with the formerly published FAQs related to the Corona/Covid-19 outbreak.

All other interesting links are gathered on our website on www.ncpflanders.be/corona

 

myOverview - sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1684 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.